India’s medical tourism market is projected to nearly double from $8.7 billion in 2025 to $16.2 billion by 2030, TravTalk reported. That growth is attributed to India’s cost competitiveness, its skilled healthcare provision, and rising international demand for treatment abroad. TravTalk reported the figure as a market projection, and it is worth reading against what the publication is and is not before it is used.

The $16.2 billion projection

A move from $8.7 billion in 2025 to $16.2 billion by 2030 implies a compound annual growth rate of roughly 13.2 per cent across the five years, TravTalk reported. That is a steep curve for any healthcare market, and it assumes a sustained rise in either patient volume or the value of each treatment. TravTalk is a travel trade publication rather than a dedicated healthcare market-intelligence firm, and it did not set out the methodology behind the $16.2 billion figure. The projection should therefore be read as indicative rather than as an audited forecast, and the attribution kept where TravTalk placed it.

The drivers TravTalk names

TravTalk named three drivers behind the projection. The first is cost competitiveness, with India continuing to offer treatment at prices well below those in Western countries. The second is skilled care, resting on experienced clinicians and advanced facilities. The third is rising global demand, the broad increase in patients willing to travel abroad for medical treatment. None of the three is new, and each has underpinned India’s medical tourism market for more than a decade. Familiarity is not the same as durability.

Medical visas and AYUSH integration

Government policy is expected to support the growth, TravTalk reported, through two instruments in particular. Streamlined medical visas are designed to move international patients through the system faster, and AYUSH integration folds India’s traditional systems into the medical tourism offer. AYUSH stands for Ayurveda, Yoga and Naturopathy, Unani, Siddha, and Homoeopathy, and its inclusion is intended to widen the range of treatment on offer to visiting patients. Both instruments sit inside India’s stated aim of strengthening its position as a global healthcare destination.

The cheaper driver, and its limits

There is a settled way to read a projection like this. Patients cross borders for care for five reasons, because the treatment abroad is better, best, cheaper, faster, or unavailable at home, and India’s market has been built firmly on cheaper. Cost competitiveness is the first driver TravTalk names, and it is the one India can defend most easily against Thailand, Turkey and Malaysia. Cheaper is also the most elastic reason to travel, and it is the first to erode when a rival destination discounts or when currency moves against the patient. A market that grows mainly on price is a market that has to keep winning on price, and a 13.2 per cent annual climb assumes India holds that edge for five years without a serious challenger closing the gap.

The skilled-care driver is the sturdier of the two. Outcomes and clinician quality are harder for a rival to replicate quickly than a price list, and a destination that competes on results rather than on cost alone is less exposed to the next discount. India’s stronger claim on the $16.2 billion is the one that rests on its hospitals and surgeons, not the one that rests on the exchange rate.

There is also the question of who converts a projection into arrivals. Inbound medical traffic is often routed through facilitators, and a growth number of this scale is as useful to the intermediaries selling visibility as it is to the hospitals delivering the care. A patient chooses a destination on trust and outcomes rather than on a market-size chart, and the distance between a $16.2 billion forecast and the individual decision to fly is exactly where facilitators operate. A projection that flatters the whole market does not, on its own, tell a single hospital where its next patient will come from.

AYUSH sits across the medical line

The AYUSH element is where the projection needs the most care. Ayurveda, Yoga and Naturopathy, Unani, Siddha, and Homoeopathy are traditional and wellness systems, and they sit toward the wellness end of the health tourism spectrum rather than at the clinical end that hospital-based medical tourism occupies. Folding AYUSH into a single medical tourism figure blends two segments that behave differently, that attract different patients, and that carry different clinical weight. A patient flying to India for cardiac surgery and a visitor booking an Ayurveda retreat are both counted, but they are not the same market, and the $16.2 billion does not say how it splits between them.

That distinction matters for anyone acting on the number. An investor weighing a hospital and an operator weighing a wellness resort are reading the same headline for two different businesses, and the projection as reported does not separate the clinical revenue from the AYUSH and wellness revenue that shares the total.

A projection of this size also says nothing about where the patients come from, and concentration is the quiet risk in any medical tourism forecast. A market that reaches $16.2 billion on the back of one or two source regions is more exposed than one that spreads its arrivals, because a visa change, a currency swing or a regional conflict in a single source market can remove a large share of the traffic at once. The TravTalk figure is a demand-side headline, and it does not describe how diversified that demand actually is.

What to watch

The useful questions are the ones TravTalk’s figure leaves open. The methodology or primary data source behind the $16.2 billion projection is the first, since without it the forecast cannot be tested. The split between hospital-based treatment and AYUSH is the second, because it decides which part of India’s medical tourism market is actually growing. Year-on-year medical visa issuance is the third and the most measurable, since visa data will show whether the patient volumes needed to reach $16.2 billion by 2030 are arriving on schedule or whether the projection is running ahead of the traffic.